Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Single Dose and Multiple Ascending Dose, Single Center Phase1 Study of Safety, Tolerability, Pharmacokinetics, and Electroencephalography of Intravenous GATE-202 in Healthy Volunteers

NCT05597241 is registered in ClinicalTrials.gov with Syndeio Biosciences, Inc as lead sponsor.

NCT NCT05597241
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05597241 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Single Dose and Multiple Ascending Dose, Single Center Phase1 Study of Safety, Tolerability, Pharmacokinetics, and Electroencephalography of Intravenous GATE-202 in Healthy Volunteers
Lead sponsor
Syndeio Biosciences, Inc
Phase
Phase 1
Overall status
Completed
Start date
October 15, 2022
Completion date
April 4, 2023
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

major depressive disorder